HOME >> BIOLOGY >> NEWS
Nexavar significantly extends overall survival by 44 percent in liver cancer patients

Chicago, IL June 4, 2007 -- Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that Nexavar (sorafenib) tablets significantly extended overall survival in patients with hepatocellular carcinoma (HCC), or primary liver cancer versus those taking placebo by 44% (HR=0.69; p-value=0.0006). Results were presented at the 43rd annual meeting of the American Society of Clinical Oncology (ASCO).

The international, Phase 3, placebo-controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) Trial randomized and evaluated 602 liver cancer patients who had no prior systemic therapy at sites in the Americas, Europe, and Australia/New Zealand. The primary objective of the study was to compare overall survival in patients administered Nexavar versus those administered placebo. Median overall survival was 10.7 months in Nexavar-treated patients compared to 7.9 months in those taking placebo.

Because there are no therapies that significantly improve survival for the thousands of patients with liver cancer, these findings demonstrate the compelling study results of Nexavar as the new reference standard of care for the first-line treatment of HCC, said Dr. Josep M. Llovet, co-principal investigator and Professor of Research, Barcelona Clinic Liver Cancer (BCLC) Group, IDIBAPS, Liver Unit, Hospital Clinic Barcelona; Director of Research, HCC Program, Associate Professor of Medicine, Mount Sinai School of Medicine, New York.

Bayer and Onyx halted the SHARP trial in February 2007 when an independent data monitoring committee determined in a pre-scheduled analysis that the overall survival endpoint had been met. There were no significant differences in serious adverse event rates between the Nexavar and placebo-treated groups, with the most commonly observed serious adverse events in patients receiving Nexavar being diarrhea and hand-foot-skin reaction. Based on the strength of the d
'"/>

Contact: Charlotte Rocker
crocker@gcigroup.com
212-537-8290
GCI Group
4-Jun-2007


Page: 1 2 3

Related biology news :

1. Adding folic acid to flour significantly reduces congenital malformations
2. Antibody linked to MS significantly higher in spinal fluid of blacks
3. Herceptin plus chemotherapy significantly increases disease-free survival in breast cancer
4. High HPV concentrations combined with smoking significantly raise risks of cervical cancer
5. Using an activated-carbon filtering pitcher significantly reduces chemicals in tap water
6. Miscarriage significantly associated with increasing paternal age
7. Regular multivitamin use near time of conception significantly reduces preeclampsia risk
8. Children born after abortion ban had significantly better educational achievements
9. Brain changes significantly after age 18, says Dartmouth research
10. New data demonstrate that Benicar and Benicar HCT significantly reduces systolic hypertension
11. Elevated inflammatory enzyme, Lp-PLA2, significantly linked to ischemic stroke

Post Your Comments:
(Date:5/19/2015)... May 19, 2015  Technology is rapidly advancing, outpacing ... in the cloud. Passwords and their management are soon ... and standards-based specifications such as those developed by the ... of passwords presents for BYOD, COPE, IoT, and mobile ... identity protocol. In response to the ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
(Date:5/27/2015)... May 27, 2015 The Medical Innovation ... impact of regulation on medical innovation, has been developed ... of Fairleigh Dickinson University’s ( FDU ) Rothman ... Alert pertains to new FDA (Food & Drug ... accelerating the approval of certain medical devices. , ...
(Date:5/26/2015)... 2015 WORMS, GERMANY – May ... (NYSE: GRA) announces that its manufacturing facility in ... certification from EXCiPACT™, an independent organization that certifies ... , All three Grace facilities that produce ... silica gels have now received GMP certification, following ...
(Date:5/26/2015)... , May 26, 2015  Sangamo BioSciences, Inc. (NASDAQ: ... president and CEO, will provide an update on the progress ... overview of the company,s business strategy at 1:30pm ET on ... Conference. The conference is being held in New ... webcast live and may be accessed via a link on ...
(Date:5/26/2015)... Global Stem Cells Group and ... company’s first cellular and regenerative medicine symposium in Barcelona ... hands-on stem cell training class Oct. 10. The event ... President of Therapeutic Confrontations (CONFTERA) in Barcelona. , ... regenerative medicine and recent advances in cellular therapies, Global ...
Breaking Biology Technology:Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3
Cached News: